Literature DB >> 6271932

Internal irradiation for cystic craniopharyngioma.

T Kobayashi, N Kageyama, K Ohara.   

Abstract

The authors report the results of internal irradiation with labeled chromic phosphate (32P) and gold-198 (198Au) colloid in eight cases of cystic craniopharyngiomas. They used a newly developed dosimetric formula, by which the radiation dose at the cyst wall and at any point far from the radioactive source can be calculated. Ten courses of irradiation in eight patients were carried out by injection of either 32P or 198Au colloid into the cyst through an Ommaya drainage system that had been placed at craniotomy. Follow-up studies ranging from 13 to 156 months revealed that all cysts were effectively treated, with elimination of fluid or collapse of the cyst. This was confirmed by Conray cystography and/or computerized tomography. Not only the dose delivered to the wall but also the thickness of the cyst wall and the location of the cyst are important factors in planning internal irradiation. A safe and adequate dose to the cyst wall could range between 9000 to 30,000 rads for craniopharyngioma. This treatment is suitable for large cysts that are thought to be difficult to remove radically, recurrent cysts resistant to previous treatment, or multiple cysts. Internal irradiation may also be applicable in other cystic intracranial tumors if dosimetry is calculated accurately.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6271932     DOI: 10.3171/jns.1981.55.6.0896

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  24 in total

1.  Treatment of craniopharyngiomas--the stereotactic approach in a ten to twenty-three years' perspective. I. Surgical, radiological and ophthalmological aspects.

Authors:  E O Backlund; B Axelsson; C G Bergstrand; A L Eriksson; G Norén; E Ribbesjö; T Rähn; P O Schnell; L Tallstedt; M Sääf
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

Review 2.  Management of primary or recurring grossly cystic craniopharyngiomas by means of draining systems. Topic review and 6 case reports.

Authors:  R Spaziante; E De Divitiis; C Irace; P Cappabianca; F Caputi
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

Review 3.  Intracavitary therapeutic options in the management of cystic craniopharyngioma.

Authors:  Adrián Cáceres
Journal:  Childs Nerv Syst       Date:  2005-07-19       Impact factor: 1.475

Review 4.  Pediatric Craniopharyngiomas: A Primer for the Skull Base Surgeon.

Authors:  Christopher Salvatore Graffeo; Avital Perry; Michael J Link; David J Daniels
Journal:  J Neurol Surg B Skull Base       Date:  2018-01-19

5.  Intracavitary treatment of intrasellar cystic craniopharyngeomas with 90-Yttrium by trans-sphenoidal approach--a technical note.

Authors:  M Lange; C M Kirsch; U Steude; R Oeckler
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

6.  SPECT using Bremsstrahlung to quantify 90Y uptake in Baker's cysts: its application in radiation synovectomy of the knee.

Authors:  T Smith; J C Crawley; D J Shawe; J M Gumpel
Journal:  Eur J Nucl Med       Date:  1988

7.  Regression of a large solid papillary craniopharyngioma following fractionated external radiotherapy.

Authors:  J Honegger; G G Grabenbauer; W Paulus; R Fahlbusch
Journal:  J Neurooncol       Date:  1999-02       Impact factor: 4.130

8.  Treatment of cystic craniopharyngioma with phosphorus-32 intracavitary irradiation.

Authors:  Rong Zhao; Jinglan Deng; Xiaoyan Liang; Jin Zeng; Xiaoyuan Chen; Jing Wang
Journal:  Childs Nerv Syst       Date:  2009-11-11       Impact factor: 1.475

9.  Management of recurrent pituitary cysts with pituitary-nasal drain.

Authors:  Umesh Dashora; David Mathias; Andy James; Ivan Zammit-Maempel; Petros Perros
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

10.  Retreatment of recurrent cystic craniopharyngioma with chromic phosphorus P 32.

Authors:  P P Kumar; R R Good; F M Skultety; E O Jones; W K Chu
Journal:  J Natl Med Assoc       Date:  1986-06       Impact factor: 1.798

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.